254 related articles for article (PubMed ID: 33787860)
1. Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection.
Yoshimori M; Shibayama H; Imadome KI; Kawano F; Ohashi A; Nishio M; Shimizu N; Kurata M; Fujiwara S; Arai A
Blood Adv; 2021 Apr; 5(7):1805-1815. PubMed ID: 33787860
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H
Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line.
Tsuge I; Morishima T; Morita M; Kimura H; Kuzushima K; Matsuoka H
Clin Exp Immunol; 1999 Mar; 115(3):385-92. PubMed ID: 10193407
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.
Siddiquey MN; Nakagawa H; Iwata S; Kanazawa T; Suzuki M; Imadome K; Fujiwara S; Goshima F; Murata T; Kimura H
Cancer Sci; 2014 Jun; 105(6):713-22. PubMed ID: 24712440
[TBL] [Abstract][Full Text] [Related]
6. Vidarabine therapy for severe chronic active Epstein-Barr virus infection.
Kimura H; Morita M; Tsuge I; Hoshino Y; Tanaka N; Ito Y; Morishima T
J Pediatr Hematol Oncol; 2001; 23(5):294-9. PubMed ID: 11464986
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-κB pathways: impairment in T cell functions.
Liu WL; Lin YH; Xiao H; Xing S; Chen H; Chi PD; Zhang G
J Virol; 2014 Jun; 88(12):6660-71. PubMed ID: 24696473
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of anti-Epstein-Barr virus antibodies in systemic chronic active Epstein-Barr virus disease.
Nishio M; Saito M; Yoshimori M; Kumaki Y; Ohashi A; Susaki E; Yonese I; Sawada M; Arai A
Front Microbiol; 2023; 14():1320292. PubMed ID: 38260896
[TBL] [Abstract][Full Text] [Related]
10. EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.
Takada H; Imadome KI; Shibayama H; Yoshimori M; Wang L; Saitoh Y; Uota S; Yamaoka S; Koyama T; Shimizu N; Yamamoto K; Fujiwara S; Miura O; Arai A
PLoS One; 2017; 12(3):e0174136. PubMed ID: 28346502
[TBL] [Abstract][Full Text] [Related]
11. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
[TBL] [Abstract][Full Text] [Related]
12. Advances in the Study of Chronic Active Epstein-Barr Virus Infection: Clinical Features Under the 2016 WHO Classification and Mechanisms of Development.
Arai A
Front Pediatr; 2019; 7():14. PubMed ID: 30805320
[TBL] [Abstract][Full Text] [Related]
13. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.
Tsuge I; Morishima T; Kimura H; Kuzushima K; Matsuoka H
J Med Virol; 2001 Jun; 64(2):141-8. PubMed ID: 11360246
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological findings of systemic Epstein-Barr virus-positive T-lymphoproliferative diseases in younger and older adults.
Wang Z; Kimura S; Iwasaki H; Takase K; Oshiro Y; Gamachi A; Makihara K; Ogata M; Daa T; Momosaki S; Takamatsu Y; Takeshita M
Diagn Pathol; 2021 Jun; 16(1):48. PubMed ID: 34088321
[TBL] [Abstract][Full Text] [Related]
15. [The road to treating chronic active Epstein-Barr viral infection].
Arai A
Rinsho Ketsueki; 2021; 62(7):835-845. PubMed ID: 34349069
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Kawada J; Ito Y; Iwata S; Suzuki M; Kawano Y; Kanazawa T; Siddiquey MN; Kimura H
Clin Cancer Res; 2014 Nov; 20(21):5412-22. PubMed ID: 25208880
[TBL] [Abstract][Full Text] [Related]
17. Dominant expression of interleukin-10 and transforming growth factor-beta genes in activated T-cells of chronic active Epstein-Barr virus infection.
Ohga S; Nomura A; Takada H; Tanaka T; Furuno K; Takahata Y; Kinukawa N; Fukushima N; Imai S; Hara T
J Med Virol; 2004 Nov; 74(3):449-58. PubMed ID: 15368517
[TBL] [Abstract][Full Text] [Related]
18. A novel mouse xenotransplantation model of EBV-T/NK-LPD and the application of the mouse model.
Imadome K
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(6):433-41. PubMed ID: 24390103
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.
Ando S; Kawada JI; Watanabe T; Suzuki M; Sato Y; Torii Y; Asai M; Goshima F; Murata T; Shimizu N; Ito Y; Kimura H
Oncotarget; 2016 Nov; 7(47):76793-76805. PubMed ID: 27732937
[TBL] [Abstract][Full Text] [Related]
20. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
